Discovery & Preclinical Services

Taking a therapy from discovery to the clinic is no easy feat.  

Companies must be able to efficiently prioritize compounds as promising candidates, unravel complex mechanisms of action, and confirm in vivo responses through biomarker signals in preparation for clinical trials. 

With CellCarta as your partner, you can tap into an extensive suite of tools and expertise to navigate the complex challenges associated with these steps, helping you carve a faster and more cost-efficient path to the clinic.  

Our discovery and preclinical offering spans a comprehensive range of services: 

• Discover new biomarkers with “omics” assays like RNA-seq, CITE-seq, and Olink Reveal 
• Analyze biomarker expression and morphology in tissue samples with our IHC, IF, and histochemical services

• Expand your preclinical dataset with genomic analysis 

• Understand physiological compound activity directly in tissue and whole blood 

• Quantify serum cytokines with multiplexed, off-the-shelf Olink and MSD assays for primate, mouse, rat, and other species 

• Monitor immune responses during treatment in disease models by flow cytometry or ELISpot 

• Characterize the stability of protein therapeutics and ADC linkers in animal plasma and tissue using target mass spectrometry 

Through industry leading histology services, tissue staining and extensive digital pathology capabilities, we are able to provide the critical insights necessary to support your biomarker discovery journey. 

Our catalog of genomics technologies can help to expand your preclinical datasets with specific direct discovery technologies in dPCR or expanded PCR panels such as the Aspyre panel for oncology biomarker testing. If the preclinical workflow requires broad insights, we offer RNA-seq, WGS, or WES with bioinformatics support. For more targeted investigation, we offer variant technologies such as HLA testing or the Oncoreveal panel from Pillar Biosciences.

We can also provide deep genomic insights into specific primary immune cell populations with our advanced cell sorting capabilities.

Learn more about what genomic services we can apply to your specific application and sample type

Take advantage of our advanced single cell analysis workflows to generate the most comprehensive multi-omic data sets — from gene and surface protein expression information to immune repertoire data. Applications range from predictive biomarker discovery and unraveling mechanisms of action to exploring drug resistance, immune exhaustion, and more.

• Get 100+ protein readouts and full transcriptome gene expression from up to 20,000 cells per sample using the 10X Genomics Chromium platform  

• Use fluorescent activated cell sorting (FACS) to further focus the power of single-cell sequencing on exact cells of interest, including rare or diseased cell subpopulations 

• Leverage our longstanding immunology experience to incorporate upstream drug treatment, cell stimulation, or other culture conditions into your single cell studies

Learn more about our single-cell sequencing offering

With experience analyzing blood and tissue samples from a range of animal models (including non-human primate, mouse, and rat models) we can help you confirm compound potency and biomarker strategies ex vivo before initiating in vivo animal studies. 

And, once in vivo studies are underway, you can collect and ship animal blood and tissue samples to us for biomarker analysis and immunophenotyping, where we use custom and high-parameter assays – including flow cytometry, multiplexed immunofluorescence, serum proteomics, and CyTOF – to complement standard panels offered by animal CROs performing the in vivo studies.  

What’s more, we can take your preclinical biomarker assays and adapt them for human clinical trials, helping you de-risk your clinical biomarker program. 

At CellCarta, we believe in beginning with the end in mind — and that developing highly relevant assays during early drug development paves the way for future success in the clinic. 

Ready to accelerate the route to clinical trials? Reach out to our discovery experts today to find out more.